3 results
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
The primary objectives are to investigate whether L-carnitine infusion may rescue lipid-induced insulin resistance and whether L-carnitine infusion is improving metabolic flexibility in the state of lipid-induced insulin resistance. Furthermore,…
The primary objectives are to investigate which determinants (primarily carnitine status) determine the effect of carnitine supplementation on metabolic flexibility and insulin sensitivity in patients with type 2 diabetes. Furthermore, a secondary…